Research programme: rhinovirus vaccine - BionaturisAlternative Names: BNT 014
Latest Information Update: 22 Aug 2016
At a glance
- Originator Bionaturis
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 22 Aug 2016 Discontinued - Preclinical for Rhinovirus infections (Prevention) in Spain (Parenteral)
- 14 Oct 2015 Preclinical trials in Rhinovirus infections in Spain (Parenteral)